Keratin 9 point mutation in the pedigree of epidermolytic hereditary palmoplantar keratoderma perturbs keratin intermediate filament network formation  by Kobayashi, Setsu et al.
FEBS 17004 FEBS Letters 386 (1996) 149-155 
Keratin 9 point mutation in the pedigree of epidermolytic hereditary 
palmoplantar keratoderma perturbs keratin intermediate filament 
network formation 
Setsu Kobayashi, Toshihiro Tanaka*, Norihisa Matsuyoshi, Sadao Imamura 
Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, 606 Japan 
Received 12 January 1996; revised version received 4 April 1996 
Abstract Keratins form an intracellular keratin filament net- 
work in keratinocytes. Point mutations in the epidermal keratins 
could lead to the disruption of keratin filament formation, 
developing skin diseases such as epidermolytic hereditary 
palmoplantar keratoderma (EHPPK). We found a G to A 
transition in keratin 9 (K9) cDNA, resulting in the substitution of 
glutamine for arginine at 162, in all patients of a pedigree of 
EHPPK. Transfection into MDCK cells and DJM-1 cells 
revealed that the plasmid CMX vector containing normal keratin 
9 cDNA showed normal keratin network formation, whereas the 
vector with a G to A point mutated keratin 9 cDNA showed 
disrupted keratin filaments with droplet formation in the cells. 
These results indicate that the point mutation seen in our patients 
had a dominant-negative effect on keratin network formation. 
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1. Introduction 
Keratins are the major structural proteins of the epidermis. 
The 10-nm keratin filaments belong to the intermediate fila- 
ment (IF) superfamily including keratins, desmin, vimentin, 
neurofilament and glial fibrillary acidic protein. All IF  pro- 
teins have a central a-helical domain, the rod, which is 
flanked by a non-helical head (amino-end) and tail (car- 
boxy-end) domains. The c~-helical sequences have repeats of 
hydrophobic amino acids, which provide a hydrophobic seal 
on the helical surface, enabling the coiled-coil structure be- 
tween two keratin polypeptides. Keratins assemble in vitro as 
obligatory heteropolymers. The highly conserved rod ends 
play a crucial role in IF  network formation [1]. The point 
mutation in keratin 5 and keratin 14 in epidermolysis bullosa 
simplex (EBS), especially the mutation in the m-helical rod 
domain, perturbs keratin filament structure and was found 
to be important for 10 nm filament assembly [2]. Transfection 
of K14 mutant cDNA into PtK2 cells showed a dysfunction in 
keratin assembly, resulting in a droplet formation of the cy- 
toskeleton [2,3]. EHPPK also shows an abnormality in keratin 
formation in patients' skin. Thus, we speculated that K9 with 
a point mutation would lead to a dominant-negative effect on 
keratin network formation. There are previous reports of 
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point mutations in the K9 gene in EHPPK [4-8] but none 
showed a function assay with these mutations. Here, we pro- 
vide the first demonstration that the point mutation found in 
a pedigree of EHPPK has a dominant-negative effect on the 
assembly of keratin intermediate filaments in the cells. 
2. Materials and methods 
2.1. PCR and DNA sequence 
Genomic DNA was extracted and purified from blood or biopsy 
specimens from the patients. The primers were designed at nucleotide 
263 282 and 664-683 based on the K9 cDNA sequence [9]. PCR 
products were digested with restriction enzymes EcoRI and XbaI. 
The digested 424 bp fragment was ligated to EcoRI/Xbal digested 
pBluescript II KS(+) (Stratagene, La Jolla, CA, USA). Double- 
stranded cDNAs inserted into pBluescript II KS(+) were sequenced 
using a Sequenase version 2.0 7-deaza-dGTP kit (US Biochemical, 
OH, USA) according to the manufacturer's recommendation. PvulI 
polymorphism was tested by digesting the PCR products from the 
family member of the patients or normal controls. The resultant 
DNA fragments were applied to 3.5% agarose gels and stained using 
ethidium bromide. 
2.2. Cell culture 
MDCK cells were grown in Dulbecco's MEM supplemented with 
10% FCS and 100 U/ml penicillin and 100 I.tg/ml streptomycin. DJM- 
1 cells were grown in Dulbecco's MEM supplemented with 10% FCS, 
100 U/ml penicillin, 100 ~tg/ml streptomycin, 0.4 I.tg/ml hydrocorti- 
sone, 10 ng/ml EGF and 84 ng/ml cholera toxin. 
2.3. Full cloning of normal and patient K9 cDNA and the construction 
of expression vectors 
PCR cloning was performed via two primer pairs, one pair corre- 
sponding to nucleotides 45 66 and 1026-1048 with an artificial Kpnl 
site, the other to nucleotides 963-984 and 1913 1932 with an artificial 
HindlII site (Fig. 1B, arrows). The former RT-PCR product was 
digested with KpnI, the latter with HindllI and subcloned into pBlue- 
script II KS(+), respectively. Each subclone was digested with KpnI/ 
internal BgllI and internal BgllI/HindlII, respectively, and these two 
fragments were ligated into pBluescript II KS(+) to make a full length 
cDNA (pK9) (Fig. 1B). For the construction of the point mutated K9 
cDNA (pK9R162Q), the KpnI/Xbal fragment was replaced with the 
patient-derived KpnI/XbaI fragment which has a G to A point muta- 
tion (Fig. 1B, bottom). The expression vector plasmid pCMX [10], 
which has a cytomegalovirus promoter and SV40 poly(A) signal, was 
digested with KpnI and HindlII. KpnI/HindlII fragments from pK9 
and pK9R162Q were purified from agarose gels and each fragment 
was ligated to this vector with the tag sequence derived from hemag- 
glutinin protein of influenza (HA). Thus, each has a normal K9 se- 
quence (K9HA) or point mutated K9 (K9R162QHA) with HA tag 
(Fig. 1A). 
2.4. Transient ransfection and immunofluorescent study 
Plasmid DNAs were purified by affinity chromatography (Quiagen, 
Chatsworth, CA, USA) followed by column chromatography with 
Bio-Gel 150 (Bio-Rad, Boston, MA, USA). MDCK cells or DJM-1 
cells were grown on glass coverslips in 6-well plates (Iwaki, Kyoto 
Japan). The cells were transfected with these DNAs using Lipofecta- 
min reagent (Gibco-BRL, Bethesda, MD, USA) according to the dis- 
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Fig. 1. Construction of K9HA and K9RI62QHA: A schematic diagram of the PCR cloning strategy for keratin 9 cDNA and construction of 
the expression vector. Arrows A and B indicate the RT-PCR primers for the 5' half of keratin 9 cDNA. Arrows C and D correspond to those 
of the 3' half. The restriction site used for full length cDNA construction (Bg/ll) and point mutation introduction into full length cDNA 
(XbaI) are indicated. ([]) CMV promoter, (ml) Tag (HA), ([1) SV40 ori, ([]) SV40 poly(A), (~1) ampicillin resistance. 
tributor's recommendation. At 24 h posttransfection, cells were fixed cubation in 0.5% Triton X-100 for 10 min. Transfected cells were 
in 3% paraformaldehyde for 10 min and were permeabilized by in- processed for double staining with immunofluorescence. Anti-HA.11 
S. Kobayashi et aL/FEBS Letters 386 (1996) 149 155 151 
A 
I I  
g 
506 
396 
298 
2Z0 
154 
I II I I I  
[ I IU  
MW 1 2 3 4 
II 
1.1: normal allele 1.1: mutant allele 11.2: normal allele 11.2: mutant allele 
T C A G T C A G T C A G T C A G 
5" IL1 9 T I C 
A ' N160 
A 
T ,, 
T 
c I s161 
T 
c I 62 G/A R/QI 
G 
C 
~- . -c  I A164 
Fig. 2. DNA sequences and PvulI mutation analysis: (A) Pedigree of the family. Solid symbols show affected individuals; open symbols, unaf- 
fected; squares, male; circles, female. (B) DNA sequences. Arrows show the G to A transition at nt 551 leading to the substitution of gluta- 
mine for arginine at 162. (C) PvulI mutation analysis. This point mutation gave rise to the new restriction site of the PvulI sequence. PCR am- 
plified fragments of 424 bp were digested by PvulI restriction enzyme. Normal alleles do not have a PvulI site. Mutant allele was digested by 
PvulI (296 and 128 bp fragments). MW: size marker. Lanes 1,2, mutant allele; lanes 3,4, normal allele. 
rabbit polyclonal antibody (Berkeley Antibody Co., CA, USA) to 
recognize the HA tag at a dilution of 1:500 was used as primary 
antibody and 1:100 diluted rhodamine-conjugated swine anti-rabbit 
IgG (Dakopatts, Glostrup, Denmark) was used as a second antibody. 
After HA tag staining, the keratin network was stained with 
MAB1629 (mouse monoclonal anti-cytokeratin 5, 8; Chemicon, CA, 
USA) for MDCK cells at a dilution of 1 : 1000 or mouse monoclonal 
anti-cytokeratin peptide 14 (Sigma Chemical Co., MO, USA) for 
DJM-1 cells to recognize the endogenous keratin network at a dilu- 
tion of 1:100 and finally 1:100 diluted fluorescein-conjugated goat 
IgG fraction to mouse IgG (Organon Teknika Corp., NC, USA) was 
used to detect he keratin network. Observations were performed with 
a Carl Zeiss LSM 410 confocal scanning laser microscope. 
3. Results and discussion 
3.1. Clinical description o f  the EHPPK patients 
The pedigree o f  the EHPPK family is descr ibed in Fig. 2A. 
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Fig. 3. Location of human EHPPK mutations relative to keratin 9 structure: Positions of mutations are shown by I". (Open square) The cen- 
tral rod domain, predicted to be largely a-helical. The rod is subdivided into helices 1A, 1B, 2A and 2B. (Hatched area) Highly conserved end 
domains of the rod; (open rectangle) non-helical head (N-terminal) and tail (C-terminal) domains. 
All affected family members showed typical hyperkeratosis on 
palms and soles with the characteristic histological finding of 
granular degradation i the epidermis [11]. 
3.2. Sequence and mutation analysis of K9 
Analysis for the K9 gene mutation was conducted on family 
members of patients and normal volunteers. By sequencing, 
we found a G to A transition at nt 551, resulting in the sub- 
stitution of glutamine for arginine at 162, in patients 1 and 2 
(Fig. 2B). A G to A transition at nt 551 gives rise to the new 
restriction enzyme recognition site corresponding to PvuII. 
Thus, we analysed PCR products by digestion with this en- 
zyme. Affected patients howed heterogenicity n this site. Fig. 
2C shows a non-digested band of 424 bp and PvuII digested 
bands of 128 and 296 bp in patients, whereas healthy mem- 
bers of this family had no PvuII restriction site within this 
area. A control study of 20 normal volunteers' genomic DNA 
revealed that there was no polymorphism in this region (data 
not shown). In previous reports on the K9 mutation, eight 
types of point mutations were reported [4-8] as summarized 
in Fig. 3. (1) M156V: substitution of valine for methionine at 
amino acid 156 by A to G transition at nt 532 [6]; (2) N160Y: 
substitution of tyrosine for asparagine at amino acid 160 by 
the transversion of A to T at nt 544 [4]; (3) N160S: serine for 
asparagine at 160 by the transversion of A to G transition at 
nt 545 [7]; (4) N160K: lysine for asparagine at 160 by T to A 
transversion at nt 546 [5]; (5) R162W: tryptophan for argi- 
nine at 162 by C to T transition at nt 550 [5,7,8]; (6) R162Q: 
glutamine for arginine at 162 by G to A transition at nt 551 
[5] (our cases have the same amino acid mutation of glutamine 
for arginine); (7) L167S: serine for leucine at 167 by transi- 
tion of T to C at nt 566 [8]; and (8) Q171P: substitution of 
proline of glutamine at 171 by A to C transversion at nt 578 
[6]. Thus, amino acids 156-171, which correspond to the head 
of the c~-helical domain of keratin intermediate filaments, may 
be a hot spot of mutation and the replacement of these amino 
acids may be crucial for keratin filament assembly and inter- 
mediate filament network formation in the cells. 
3.3. Expression of K9 HA and K9R162QHA in MDCK cells 
and DJM-1 cells 
The point mutation of the keratin 14 rod domain seen in 
the EBS patients has a dominant-negative effect on keratin 
network formation in epithelial cells [3]. We transfected nor- 
mal keratin 9 cDNA (K9HA) or point mutated K9 
(K9RI62QHA) found in our pedigree into MDCK cells or 
DJM-1 cells, since there is no experimental evidence that the 
mutations in the rod domain of keratin 9 had a dysfunction- 
ing effect on keratin intermediate filament assembly. Fig. 4 
demonstrates the staining results on the Tag sequence (HA) 
derived from transfected K9HA and K9R162QHA cDNAs 
and the endogenous keratin network by keratin staining and 
overlaying. Both the epithelial cell derived cell line, MDCK, 
and the epidermal cell derived cell line, DJM-1, showed essen- 
Fig. 4. Immunofluorescence analysis of transfected MDCK cells and DJM-1 cells: MDCK cells (A-F) and DJM-1 cells (GL) were transfected 
with pK9HA (A-C, G-I) and pK9R162QHA (D-F, J L). 24 h posttransfection, cells were fixed and were processed for double immunofluores- 
cence. The pk9HA and pK9R162QHA products were detected by anti-HA.11 rabbit polyclonal antibody through a 488 nm argon laser 
(A,D,G,J). The endogenous keratins were detected with mouse monoclonal anti-cytokeratin 8 for MDCK cells (B,E) or mouse monoclonal 
anti-cytokeratin peptide 14 for DJM-1 ceils (H,K), through a 543 nm HeNe laser. The yellow color in C, F, I, L demonstrates the superposi- 
tioning of the colocalization through overlaying the 488 nm and 543 nm laser. 
A 
K9 revealed roplet formation (Fig. 4D,J). Endogenous ker- 
atin filament stained by anti-keratin antibody is demonstrated 
by the green signal (argon 488 nm laser). All the cells revealed 
tially the same result. As shown by the red signal (HeNe 543 
nm laser) K9 protein showed filament formation in wild type 
cDNA transfected cells (Fig. 4A,G), whereas point mutated 
B 
C 
D 
S. Kobayashi et al./FEBS Letters 386 (1996) 149 155 153 
F 
J G 
H 
I 
154 S. Kobayashi et al./FEBS Letters 386 (1996) 149-155 
K 
I_ 
Fig. 4 (continued). 
keratin fibers. Within these cells, mutated K9 cDNA trans- 
fected cells showed droplets within the cell (Fig. 4E,K), 
whereas wild type K9 cDNA transfected cells showed a fiber 
structure only (Fig. 4B,H). Thus, the point mutation in K9 
disrupts the endogenous keratin network in the cells. These 
results are in line with the observation of droplet formation 
with point mutated keratin 14 cDNA transfected cells [3]. To 
confirm whether the point mutated K9 droplets and endoge- 
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nous keratin droplets are identical, we performed further ana- 
lysis by confocal microscopy using 488 nm and 543 nm laser 
light. The yellow colored droplet in Fig. 4F and L clearly 
demonstrates the colocalization of the K9R162QHA product 
and internal keratin in droplet formation within the trans- 
fected cells. These results indicate that the keratin intermedi- 
ate filament structure integrated by the newly expressed 
K9R162QHA product collapses and shows the formation of 
droplets in MDCK cells and DJM-1 cells and that the point 
mutation seen in our pedigree does have a dominant-negative 
effect on filament formation in the cells. 
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